Park, Se Hoon

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

Cristescu, R., Lee, J., Nebozhyn, M., Kim, K.-M., Ting, J. C., Wong, S. S., Liu, J., Yue, Y. G., Wang, J., Yu, K., et al. (2015) · Nature Medicine

Gastric Cancer Management and OutcomesCancer Genomics and Diagnostics

Cited by 2,223

Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma

Bajorin, D. F., Witjes, J. A., Gschwend, J. E., Schenker, M., Valderrama, B. P., Tomita, Y., Bamias, A., Lebret, T., Shariat, S. F., Park, S. H., et al. (2021) · New England Journal of Medicine

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 1,065

Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study

Antonarakis, E. S., Piulats, J. M., Gross-Goupil, M., Goh, J., Ojamaa, K., Hoimes, C. J., Vaishampayan, U., Berger, R., Sezer, A., Alanko, T., et al. (2020) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchCancer Immunotherapy and Biomarkers

Cited by 736

Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy

Kim, S. T., Lim, D. H., Jang, K.-T., Lim, T., Lee, J., Choi, Y.-L., Jang, H.-L., Yi, J. H., Baek, K. K., Park, S. H., et al. (2011) · Molecular Cancer Therapeutics

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 145

Comprehensive pharmacogenomic characterization of gastric cancer

Sa, J. K., Hong, J. Y., Lee, I.-K., Kim, J.-S., Sim, M.-H., Kim, H. J., An, J. Y., Sohn, T. S., Lee, J. H., Bae, J. M., et al. (2020) · Genome Medicine

Gastric Cancer Management and OutcomesCancer Genomics and Diagnostics

Cited by 46